Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care (TNDM) delivers innovative insulin management solutions through advanced pump technology and connected diabetes care platforms. This news hub provides investors and healthcare professionals with timely updates on corporate developments, product milestones, and regulatory progress.
Access official press releases covering quarterly financial results, new product clearances, and strategic partnerships alongside analysis of market trends impacting diabetes care technology. Our curated collection ensures you stay informed about pump software updates, clinical trial outcomes, and international expansion efforts.
Key updates include FDA submissions, insulin delivery system enhancements, and operational developments across global markets. Bookmark this page for direct access to Tandem Diabetes' latest announcements, including pump compatibility improvements and user experience initiatives that shape modern diabetes management.
Tandem Diabetes Care (NASDAQ: TNDM) has issued a voluntary medical device correction for select t:slim X2 insulin pumps due to a critical speaker-related issue. The problem can trigger a Malfunction 16 alarm that stops insulin delivery and CGM communication, potentially leading to dangerous hyperglycemia.
The company has reported 700 confirmed adverse events and 59 reported injuries, with no deaths. Between July 22-24, 2025, affected U.S. customers received direct notifications. Tandem plans to release a software update to enhance early speaker failure detection and implement persistent vibration alerts to reduce safety risks.
Tandem Diabetes Care (NASDAQ: TNDM) reported its Q2 2025 financial results and updated full-year guidance. The company achieved record Q2 sales of $240.7 million, including $70.5 million from international markets. Q2 highlights include improved gross margins of 52% and pump shipments of 21,000 units in the U.S. and 9,000 internationally.
The company expects to reach a significant milestone of $1 billion in worldwide sales for 2025, with $700 million from U.S. sales and $300 million from international markets. However, TNDM reported a GAAP operating loss of $51.8 million (22% of sales) and adjusted its EBITDA margin guidance to negative 5% for the full year.
Notable developments include initiating an early access program for t:slim X2 with Control-IQ+ technology integrated with Abbott's FreeStyle Libre 3 Plus, receiving CE Mark for Tandem Mobi, and advancing pharmacy benefit initiatives for Q4 2025.
Tandem Diabetes Care (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, has announced its participation in three upcoming investor conferences in August and September 2025.
The company will present at the Canaccord Genuity Growth Conference on August 12 at 1:00 PM ET, the Morgan Stanley Global Healthcare Conference on September 10 at 9:15 AM ET, and will host meetings at the Bernstein Healthcare Forum on September 24. All presentations will be available via webcast on the company's investor relations website for 30 days.
Tandem Diabetes Care (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025 after market close.
The company will host a conference call and webcast at 4:30 PM Eastern Time on the same day to discuss the quarterly results. Investors can access the live webcast through Tandem's Investor Center website, with a recording available for 30 days afterward.
Tandem Diabetes Care (NASDAQ: TNDM), a leader in insulin delivery and diabetes technology, has announced its participation in three major upcoming investor conferences in May and June 2025:
- RBC Capital Markets Global Healthcare Conference on May 20, 2025 at 10:00am ET
- Jefferies Global Healthcare Conference on June 4, 2025 at 3:45pm ET
- Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025 at 8:40am ET
Management will present company updates at each conference. All presentations will be available via live webcast and archived for 30 days on Tandem's Investor Center website.
Tandem Diabetes Care reported strong Q1 2025 financial results, with worldwide sales growing 22% to $234.4 million. The company achieved record first-quarter performance, with U.S. pump sales increasing 19% and significant international growth.
Key highlights include:
- Worldwide pump shipments exceeded 28,000 units
- International sales reached $83.8 million
- U.S. sales showed robust growth with over 17,000 pump shipments
- 5-point improvement in adjusted EBITDA margin
- 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi
The company reaffirmed its 2025 guidance, projecting full-year sales between $997 million to $1.007 billion. Despite posting a GAAP net loss of $130.6 million, Tandem's non-GAAP metrics showed operational improvements, with gross margin reaching 51% compared to 49% in the previous year.
Tandem Diabetes Care (TNDM), a leading insulin delivery and diabetes technology company, has scheduled its first quarter 2025 financial results announcement for April 30, 2025, after market close.
The company will host a conference call and simultaneous webcast at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss Q1 2025 financial and operating results. Investors can access the live webcast through Tandem's Investor Center website, and a recording will be available for 30 days afterward.
Tandem Diabetes Care (TNDM) announced positive results from its pivotal trial of Control-IQ+ automated insulin delivery technology for type 2 diabetes, published in The New England Journal of Medicine. The 13-week study showed significant improvements in glycemic control across a diverse population of 319 participants.
Key findings include:
- A1C reduction of 0.9% in Control-IQ+ group vs 0.3% in control group
- 2.3% A1C reduction in participants with baseline A1C ≥9%
- Time in range improved by 16%, adding 3.8 more hours/day in target range
- Insulin use decreased by 8 units/day in Control-IQ+ group
The study demonstrated effectiveness across diverse demographics, with 39% of participants from minority backgrounds. The technology proved safe with no new safety concerns, and received high usability scores regardless of participants' bolusing strategy.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
